Chugai Pharmaceutical Co., Ltd.
Stock Price Chart
2026/11/12 13:15 UpdatedPrice Trend
2026/11/12 13:15 UpdatedPrice & Trading Details
2026/11/12 13:15 UpdatedPRICE
TRADING
Analyst Recommendations 15 analysts
Updated 2026/11/01Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/10/27 | ¥79.86 | ¥87.20 | +9.2% |
| 2026/07/24 | ¥74.57 | ¥70.69 | -5.2% |
| 2026/04/24 | ¥68.59 | ¥70.13 | +2.3% |
| 2026/01/28 | ¥72.09 | ¥78.02 | +8.2% |
Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
9.4M | +0.57% | |
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
8.3M | -3.97% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
6.3M | +1.14% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
5.1M | +1.49% | |
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
4.8M | -1.67% | |
|
T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Overseas Stock Fd.
|
3.7M | -1.74% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
1.2M | +203.06% |
Dividend History
Updated 2026/11/08| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥66 | -75.7% |
| 2025 | ¥272 | +177.6% |
| 2024 | ¥98 | +22.5% |
| 2023 | ¥80 | +2.6% |
| 2022 | ¥78 | - |
Financial Performance
2026/11/08 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥999,758M | ¥1,259,726M | ¥1,111,367M | ¥1,170,611M |
| Gross Profit | ¥661,612M | ¥783,475M | ¥698,061M | ¥831,201M |
| Operating Income | ¥421,897M | ¥533,308M | ¥439,174M | ¥542,002M |
| Pretax Income | ¥419,433M | ¥531,227M | ¥443,848M | ¥542,002M |
| Net Income | ¥302,995M | ¥374,429M | ¥325,472M | ¥387,317M |
| EPS | ¥184.17 | ¥227.57 | ¥197.80 | ¥235.36 |
| Operating Margin | 42.20% | 42.34% | 39.52% | 46.30% |
| Balance Sheet | ||||
| Total Assets | ¥1,538,694M | ¥1,869,758M | ¥1,932,547M | ¥2,208,373M |
| Total Equity | ¥1,188,017M | ¥1,424,387M | ¥1,625,580M | ¥1,901,499M |
| Total Liabilities | ¥350,677M | ¥445,371M | ¥306,967M | ¥306,874M |
| Cash | ¥267,753M | ¥222,169M | ¥458,674M | ¥540,202M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 77.21% | 76.18% | 84.12% | 86.10% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥279,626M | ¥243,582M | ¥409,925M | ¥447,600M |
| Investing CF | -¥118,927M | -¥145,465M | -¥37,290M | -¥227,365M |
| Financing CF | -¥107,408M | -¥145,641M | -¥139,331M | -¥141,006M |
| Free CF | ¥206,760M | ¥172,343M | ¥335,667M | ¥392,701M |
| Efficiency | ||||
| ROE | 25.50% | 26.29% | 20.02% | 20.37% |
| ROA | 19.69% | 20.03% | 16.84% | 17.54% |
Latest IR Information
-
Chugai Pharmaceutical Co., Ltd. Financial Summary for the Third Quarter of the Fiscal Year Ending December 2026 [IFRS]
For the nine months ended the third quarter of the fiscal year ending December 2026, consolidated revenue was 1,068,074 million yen (YoY +17.2%), operating profit was 522,570 million yen (+21.6%), and net income was 375,302 million yen (+22.8%), all showing...
Read more -
Chugai Pharmaceutical Co., Ltd. Supplemental Materials for Consolidated Financial Results for the Three Months Ended September 30, 2026 (IFRS)
Discloses adjustments reconciling IFRS results to Core results. Revenue was 911.6 billion yen (IFRS) → adjusted to 1,068.1 billion yen (Core cumulative), etc. Operating income was 429.8 billion yen (IFRS), adjusted to 536.1 billion yen cumulative. Outlook for Q4 onward...
Read more -
F. Hoffmann-La Roche 2026 Q3 Sales Performance
F. Hoffmann-La Roche announced sales performance for January–September 2026. Roche Holding holds a majority of shares, and the Company's results include figures from the Roche Group. The published materials are posted on the Roche Group website.
Read more -
Notice on Discontinuation of GYM329 (emugrobart) Obesity Development, License Return and Resumption of SMA Development
Announced discontinuation of emugrobart obesity development and return of license. Began preparations to resume development in the SMA area. No impact on consolidated earnings forecasts for the fiscal year ending December 2026.
Read more -
Chugai Pharmaceutical 2026 Midterm Financial Results | Details of Revenue and Profit
Chugai Pharmaceutical achieved net sales of approximately 663.3 billion yen (up 14.7% YoY) for the second quarter (midterm) of the fiscal year ending December 2026, maintaining solid performance. Operating income also grew significantly to approximately 319.6 billion yen (+16.9%), and...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥8,447
Rating Score: 2.00 (Based on 15 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
